IntroductionPsilocybin shows encouraging outcomes for patients with cancer and major depressive disorder (MDD). However, there is insufficient evidence on the use of evidence-based psychotherapeutic interventions to consistently guide and standardize psilocybin preparation, dosing, and integration. Meaning-centered psychotherapy (MCP) is a manualized, brief ...
Unknown journal
2025-07-29
Rosa WE, Napolitano S, McAndrew N, Jenkins B, Lichtenthal WG, Applebaum AJ, Breitbart W, Agrawal M.
Europe PMC Published
psilocybin DepressionAgingClinical TrialObservational Study Clinical Trial
BackgroundFluoxetine remains the only pharmacological treatment approved for Bulimia Nervosa, and no other drugs have been approved for eating disorders (EDs). The rationale for exploring psilocybin as a treatment for EDs is compelling, both from biological and psychological perspectives. Moreover, its safety profile in healthy individuals appears favorable....
Unknown journal
2025-07-28
Bevione F, Lacidogna MC, Lavalle R, Abbate Daga G, Preti A.
Europe PMC Published
psilocybin Eating DisordersClinical TrialRandomized Controlled TrialSystematic ReviewReview ArticleCase ReportObservational StudySafety Randomized Controlled Trial HumansHallucinogens
Abstract Classical psychedelics such N,N -dimethyltryptamine (DMT), psilocybin, and lysergic acid diethylamide (LSD) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine-mimicking the pharmacological profile of ay...
Research Square
2025-07-26
Egger K, Bozsak R, Aicher H, Sari H, Poetzsch S, Rominger A, Martin-Soelch C, Dornbierer D, Quednow B, Scheidegger M, Cumming P.
Europe PMC PREPRINT (not peer reviewed)
psilocybin Brain ImagingPharmacologyReceptor PharmacologyConsciousnessAgingHealthy Volunteers Other
Sleep paralysis (SP), an REM parasomnia, can be characterized as one of the symptoms of narcolepsy. The SP phenomenon involves regaining meta-consciousness by the dreamer during REM, when the physiological atonia of skeletal muscles is accompanied by visual and auditory hallucinations that are perceived as vivid and distressing nightmares. Sensory impression...
Unknown journal
2025-07-25
Rudy LM, Godlewski MM.
Europe PMC Published
psilocybin Mechanism of ActionReceptor PharmacologyConsciousnessReview ArticleDrug Interactions Review Article AnimalsHumans
The resurgence of psychedelic-assisted psychotherapy marks a pivotal evolution in mental health treatment, challenging traditional paradigms by integrating compounds such as psilocybin, LSD, MDMA, and ketamine into clinical practice. Historically marginalized due to regulatory and societal concerns, these agents are now gaining recognition for their unique n...
Unknown journal
2025-07-24
Askariyan K, Joghataei MT, Dehghan S, Nohesara S, Riahi Pour L, Mohammadi MH, Ahmadirad N.
Europe PMC Published
psilocybin DepressionPTSDAddictionMechanism of ActionReceptor PharmacologyReview ArticleObservational Study Review Article AnimalsHumans
Background and aimsPsilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin-assisted psychotherapy f...
Unknown journal
2025-07-23
Luquiens A, Belahda D, Graux C, Igounenc N, Serrand C, Rochefort P, Mura T, Sergent F.
Europe PMC Published
psilocybin DepressionAddictionClinical TrialRandomized Controlled TrialSafetyAdverse Events Randomized Controlled Trial
BackgroundThere are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders ("MED-FED") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for thei...
Unknown journal
2025-07-23
Rodan SC, Meez N, Lloyd-Hurwitz S, Bedoya-Pérez MA, Suraev A, Sommer N, Greenstien K, Maguire S, McGregor IS.
Europe PMC Published
psilocybin PTSDEating DisordersMicrodosingClinical TrialObservational StudySafety Clinical Trial
This viewpoint reconceptualizes mysticism and fundamentalism as brain network disorders, with psychedelics like psilocybin, lysergic acid diethylamide, and N,N-dimethyltryptamine offering potential to modulate these states. By disrupting rigid neural patterns, psychedelics may foster cognitive flexibility, challenge inflexible belief systems, and offer thera...
Unknown journal
2025-07-22
Yang A, Lv X, Wang H, Wang X.
Europe PMC Published
psilocybin SpiritualityMystical Experience Other BrainHumans
Psilocybin's efficacy as a treatment for treatment-resistant depression (TRD) has led to a wave of new legislation permitting its usage in medical settings. Older adults are affected disproportionately by TRD and may be especially good candidates for this promising treatment. However, due to the drug's past (and present) illicit status and exposure to histor...
Unknown journal
2025-07-22
Gillespie CM, Bering JM.
Europe PMC Published
psilocybin DepressionAgingOlder AdultsTreatment-Resistant Depression Other HumansHallucinogens
BackgroundPeople with HIV (PWH) are disproportionately affected by cigarette use, with a 40 - 70% prevalence rate. Although many express a strong interest in quitting, many PWH who smoke experience lower cessation rates with traditional treatments, in part due to their comorbid anxiety and depressive symptoms. Psilocybin, a classic psychedelic referred to as...
Unknown journal
2025-07-20
Cioe PA, Stang GS, Azam D, Dugal S.
Europe PMC Published
psilocybin DepressionAnxietyAddictionSafetyAdverse Events Qualitative Study HumansHIV Infections
Determining the scale of neural representations is a central challenge in neuroscience. While localized representations have traditionally dominated, evidence suggests information is also encoded in distributed, hierarchical networks. Recent research indicates that the hierarchy of causal influences shaping functional patterns serves as a signature of distin...
Unknown journal
2025-07-20
Socoró-Garrigosa M, Perl YS, Kringelbach ML, Erritzoe D, Nutt DJ, Carhart-Harris R, Vohryzek J, Deco G.
Europe PMC Published
psilocybin DepressionNeuroplasticity Other BrainHumans
BackgroundThis study is the first to formally evaluate in humans the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RE104, a prodrug of the synthetic psychedelic known as 4-hydroxy-N,N-diisopropyltryptamine or 4-OH-DiPT.MethodsThis double-blind, randomized, placebo-controlled, phase 1 study of single subcutaneous (SC) doses of RE104 (5 ...
Unknown journal
2025-07-20
Ludbrook G, Bryson N, Taylor B, Hocevar-Trnka J, Johnson MW, Hirman J, Morrish G, Alexander R, Pollack M.
Europe PMC Published
psilocybin PharmacologyMystical ExperienceClinical TrialObservational StudySafetyAdverse Events Clinical Trial HumansHallucinogens
Those living with chronic pain and comorbid functional disabilities are often confronted by a physically and emotionally transformative experience, impacting their identity and ability to derive meaning in life. Despite the use of various pharmacological and non-pharmacological treatments to moderate symptoms, the degree of analgesia and functional recovery ...
Unknown journal
2025-07-20
Cherup NP, Finan PH.
Europe PMC Published
psilocybin DepressionAnxietyChronic PainConsciousnessEmotional Processing Other HumansHallucinogens
The classical psychedelics (+)-lysergic acid diethylamide (LSD), psilocybin, and mescaline exert their psychedelic effects via activation of the 5-HT2A serotonin receptor (5-HT2AR). Recent clinical studies have suggested that classical psychedelics may additionally have therapeutic potential for many neuropsychiatric conditions including depression, anxiety,...
Unknown journal
2025-07-17
Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL.
Europe PMC Published
psilocybin DepressionAnxietyPTSDHeadache / MigrainePharmacologyReceptor Pharmacology Other AnimalsHumans
Accumulating evidence suggests that psilocybin can produce rapid and sustained clinical benefits when administered in conjunction with psychological support. Though non-pharmacological procedures are considered integral, the field lacks therapeutic guidelines and little is known about current practices. This systematic review sought to provide a comprehensiv...
Unknown journal
2025-07-17
Kittur ME, Burgos M LA, Jones BDM, Blumberger DM, Mulsant BH, Rosenblat JD, Husain MI.
Europe PMC Published
psilocybin DepressionAddictionOCDEating DisordersMechanism of ActionClinical TrialSystematic ReviewReview ArticleTreatment-Resistant Depression Systematic Review HumansHallucinogens
The therapeutic potential of psychedelic substances, particularly psilocybin, for treatment-resistant depression (TRD) has garnered considerable attention. However, the necessity of subjective psychedelic experiences for therapeutic efficacy remains unclear, creating a critical gap in the field. To determine whether subjective psychedelic experiences induced...
Unknown journal
2025-07-15
Fernández-Borkel T, Borkel LF, Rojas-Hernández J, Hernández-Álvarez E, Quintana-Hernández DJ, Ponti LG, Henríquez-Hernández LA.
Europe PMC Published
psilocybin DepressionAnxietyBrain ImagingConsciousnessRandomized Controlled TrialTreatment-Resistant Depression Randomized Controlled Trial
BackgroundClassic psychedelics, such as psilocybin and LSD, evoke certain kinds of altered states of consciousness. Specific features of the experience, such as its allegedly ineffable nature, have been discussed as posing challenges to the informed consent process. A growing call for tailored informed consent documents (ICDs) in the psychedelic bioethics li...
Unknown journal
2025-07-15
Cheung K, Propes C, Graziosi M, Patch K, Yaden DB.
Europe PMC Published
psilocybin ConsciousnessClinical TrialReview ArticleSafety Clinical Trial HumansHallucinogens
Psilocybe species, commonly known as "magic mushrooms", are a group of hallucinogenic fungi known for their psychoactive compounds such as psilocybin, psilocin, baeocystin, and norbaeocystin. These species have been the focus of scientific study due to their potential therapeutic applications, despite their classification as controlled substances in many jur...
Unknown journal
2025-07-14
Sudhakaran G, Chakraborty S, Kumar A, Bharti SAK, Csaba V, Valan Arasu M, Namasivayam SKR, Arockiaraj J.
Europe PMC Published
psilocybinpsilocin DepressionAnxietyPTSDAddictionHeadache / MigraineMechanism of ActionReview Article Review Article AnimalsHumans
BackgroundRecent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression. However, limited data exists on Australian mental healthcare providers' attitudes, knowledge and readiness to implement with psychedelic-assisted psychotherapy.MethodsA...
Unknown journal
2025-07-14
Nadeem Z, Parker S, McGovern H, Sebben B, Oestreich LK.
Europe PMC Published
psilocybin DepressionPTSDObservational StudyTreatment-Resistant DepressionHealthcare WorkersSafety Observational Study HumansHallucinogens
Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TBI is characterized by neuroinflammation, oxidative stress, impaired neuroplasticity, imbalances in neurotransmission, and cell death - factors that contribute to the development of neurological and psychiatric dis...
Unknown journal
2025-07-13
Plummer Z, Allen J, Brand J, Mayo LM, Shultz SR, Christie BR.
Europe PMC Published
psilocybin NeuroplasticityMechanism of ActionReceptor PharmacologyOxidative StressReview ArticleAnimal StudySafetyInflammation Review Article AnimalsHumans
